Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,031 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema.
Atsukawa M, Tsubota A, Kato K, Abe H, Shimada N, Asano T, Ikegami T, Koeda M, Okubo T, Arai T, Nakagawa-Iwashita A, Yoshida Y, Hayama K, Itokawa N, Kondo C, Chuganji Y, Matsuzaki Y, Iwakiri K. Atsukawa M, et al. Among authors: yoshida y. J Gastroenterol Hepatol. 2018 Jun;33(6):1256-1263. doi: 10.1111/jgh.14047. Epub 2018 Feb 19. J Gastroenterol Hepatol. 2018. PMID: 29215154
Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease.
Arai T, Atsukawa M, Tsubota A, Koeda M, Yoshida Y, Okubo T, Nakagawa A, Itokawa N, Kondo C, Nakatsuka K, Masu T, Kato K, Shimada N, Hatori T, Emoto N, Kage M, Iwakiri K. Arai T, et al. Among authors: yoshida y. Dig Liver Dis. 2019 Jul;51(7):1036-1042. doi: 10.1016/j.dld.2018.12.022. Epub 2019 Jan 9. Dig Liver Dis. 2019. PMID: 30683615
Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease.
Arai T, Atsukawa M, Tsubota A, Kawano T, Koeda M, Yoshida Y, Tanabe T, Okubo T, Hayama K, Iwashita A, Itokawa N, Kondo C, Kaneko K, Kawamoto C, Hatori T, Emoto N, Iio E, Tanaka Y, Iwakiri K. Arai T, et al. Among authors: yoshida y. PLoS One. 2019 Nov 13;14(11):e0224184. doi: 10.1371/journal.pone.0224184. eCollection 2019. PLoS One. 2019. PMID: 31721770 Free PMC article.
Serum soluble sialic acid-binding immunoglobulin-like lectin-7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with non-alcoholic fatty liver disease.
Sakamoto Y, Yoshio S, Doi H, Kawai H, Shimagaki T, Mori T, Matsuda M, Aoki Y, Osawa Y, Yoshida Y, Arai T, Itokawa N, Ito T, Seko Y, Yamaguchi K, Itoh Y, Mise Y, Saiura A, Taketomi A, Kanto T. Sakamoto Y, et al. Among authors: yoshida y. Hepatol Res. 2020 Apr;50(4):466-477. doi: 10.1111/hepr.13464. Epub 2019 Dec 26. Hepatol Res. 2020. PMID: 31808236
Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.
Atsukawa M, Tsubota A, Takaguchi K, Toyoda H, Iwasa M, Ikegami T, Chuma M, Nozaki A, Uojima H, Hiraoka A, Fukunishi S, Yokohama K, Tada T, Kato K, Abe H, Tani J, Okubo H, Watanabe T, Hattori N, Tsutsui A, Senoh T, Yoshida Y, Okubo T, Itokawa N, Nakagawa-Iwashita A, Kondo C, Arai T, Michitaka K, Iio E, Kumada T, Tanaka Y, Takei Y, Iwakiri K. Atsukawa M, et al. Among authors: yoshida y. J Gastroenterol Hepatol. 2020 Jul;35(7):1229-1237. doi: 10.1111/jgh.14965. Epub 2020 Jan 14. J Gastroenterol Hepatol. 2020. PMID: 31881554
Prevalence and characteristics of portopulmonary hypertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization.
Atsukawa M, Tsubota A, Hatano M, Kondo C, Shioda K, Ohno H, Kawano T, Hayama K, Arai T, Nakagawa-Iwashita A, Itokawa N, Kaneko K, Yoshida Y, Koeda M, Okubo T, Yamamoto T, Yamamoto T, Taniai N, Yoshida H, Kanazawa H, Shimizu W, Iwakiri K. Atsukawa M, et al. Among authors: yoshida y, yoshida h. Hepatol Res. 2020 Nov;50(11):1244-1254. doi: 10.1111/hepr.13560. Epub 2020 Sep 1. Hepatol Res. 2020. PMID: 32822521
Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B.
Itokawa N, Atsukawa M, Tsubota A, Takaguchi K, Nakamuta M, Hiraoka A, Kato K, Abe H, Mikami S, Shimada N, Chuma M, Akito N, Uojima H, Ogawa C, Asano T, Tani J, Morishita A, Senoh T, Yamashita N, Oikawa T, Matsumoto Y, Koeda M, Yoshida Y, Tanabe T, Okubo T, Arai T, Hayama K, Iwashita AN, Kondo C, Tada T, Toyoda H, Kumada T, Iwakiri K. Itokawa N, et al. Among authors: yoshida y. JGH Open. 2020 Nov 2;5(1):34-40. doi: 10.1002/jgh3.12443. eCollection 2021 Jan. JGH Open. 2020. PMID: 33490611 Free PMC article.
Factors Associated with Hepatitis B Surface Antigen Kinetics and Responses in Pegylated Interferon Alpha-2a Monotherapy for Patients with Chronic Hepatitis B.
Itokawa N, Atsukawa M, Tsubota A, Shimada N, Toyoda H, Takaguchi K, Hiraoka A, Senoh T, Koeda M, Yoshida Y, Okubo T, Arai T, Hayama K, Nakagawa-Iwashita A, Kondo C, Iwakiri K. Itokawa N, et al. Among authors: yoshida y. Intern Med. 2021;60(4):507-516. doi: 10.2169/internalmedicine.5432-20. Epub 2021 Feb 15. Intern Med. 2021. PMID: 33583931 Free PMC article.
7,031 results